T9G — Vidac Pharma Holding Income Statement
0.000.00%
Last trade - 00:00- €26.73m
- €27.36m
Annual income statement for Vidac Pharma Holding, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 5 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 0.407 | 0.609 | 1.21 | 1.11 |
| Operating Profit | -0.407 | -0.609 | -1.21 | -1.11 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -0.406 | -0.643 | -1.27 | -1.39 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.406 | -0.643 | -1.27 | -1.39 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.406 | -0.643 | -1.27 | -1.39 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.406 | -0.643 | -1.27 | -1.39 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.008 | -0.012 | -0.024 | -0.024 |
| Dividends per Share |